HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Acurx Pharmaceuticals (NASDAQ:ACXP) and maintained a price target of $13.
September 13, 2023 | 10:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acurx Pharmaceuticals' stock has been reiterated as a 'Buy' by HC Wainwright & Co. with a maintained price target of $13.
The reiteration of a 'Buy' rating by a reputable analyst like Ed Arce from HC Wainwright & Co. is a positive signal for Acurx Pharmaceuticals. The maintained price target of $13 also indicates a positive outlook for the stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100